Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3
The experimentally established mechanism targets of Labetalol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 known ✓ | P08588 | 9/20 | 0.63 |
| ▸ | ADRB2 known ✓ | P07550 | 8/20 | 0.63 |
| ▸ | ADRA1A known ✓ | P35348 | 5/20 | 0.63 |
| ▸ | ADRA1D known ✓ | P25100 | 4/20 | 0.63 |
| ▸ | ADRA1B known ✓ | P35368 | 4/20 | 0.63 |
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.63 |
| ▸ | ADRB3 known ✓ | P13945 | 10/20 | 0.62 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.62 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.62 |
| ▸ | HTR1A | P08908 | 5/20 | 0.63 |
| ▸ | LMNA | P02545 | 4/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.63 |
| ▸ | HPGD | P15428 | 2/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.63 |
| ▸ | DRD3 | P35462 | 2/20 | 0.63 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Labetalol SCHEMBL888086 | 0.89 | ADRB1 (0.68) | ADRB1ADRB2ADRA1AHTR1ALMNA | |
| Labetalol SCHEMBL4667366 | 0.84 | ADRB1 (0.67) | ADRB1ADRB2ADRA1AHTR1ALMNA | |
| Labetalol SCHEMBL10863742 | 0.84 | ADRB1 (0.45) | ADRB1ADRB2ADRA1AHTR1ALMNA | |
| Labetalol SCHEMBL5885719 | 0.82 | ADRB2 (0.62) | ADRB1ADRB2ADRA1AHTR1ALMNA | |
| Labetalol SCHEMBL9837071 | 0.81 | ADRB2 (0.69) | ADRB1ADRB2ADRA1AHTR1ALMNA | |
| Labetalol SCHEMBL9837906 | 0.80 | ADRB2 (0.68) | ADRB1ADRB2ADRA1AHTR1ALMNA | |
| Labetalol SCHEMBL10356800 | 0.80 | ADRB1 (1.00) | ADRB1ADRB2ADRA1AHTR1ALMNA | |
| Dilevalol SCHEMBL79468 | 0.80 | ADRB1 (1.00) | ADRB1ADRB2ADRA1AHTR1ALMNA | |
| Labetalol SCHEMBL41231 | 0.80 | ADRB1 (1.00) | ADRB1ADRB2ADRA1AHTR1ALMNA | |
| Labetalol SCHEMBL4582 | 0.80 | ADRB1 (1.00) | ADRB1ADRB2ADRA1AHTR1ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112134-A1 | Tricyclic Antagonists of Prostaglandin D2 Receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112134-A1 | Tricyclic Antagonists of Prostaglandin D2 Receptors | PTGDR, PTGDR2, PTGER2 | ADRB1 87/4885ADRB2 23/4885ADRA1A 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.